| Outcome Measures: |
Primary: Incidence rates of adverse events, specifically genital infections, urinary tract infections, increased haematocrit, renal impairment, hepatic impairment, bone fractures and cancers, in particular breast, bladder, and prostate cancers, Assessed in patients with Type 2 diabetes who are treated with Forxiga in routine Australian clinical practice, Up to 6 months|Any early adverse effects as a result of drug interactions in patients with Type 2 diabetes who are treated with Forxiga in routine Australian clinical practice, Up to 6 months|Incidence rates of spontaneously reported hypoglycaemia in patients with Type 2 diabetes who are treated with Forxiga in routine Australian clinical practice, Up to 6 months | Secondary: Rate of prescribing of Forxiga after its introduction to routine Australian clinical practice, Upto 6 months|Indication for prescription of Forxiga in routine Australian clinical practice, Upto 6 months|Change in efficacy and safety variables after treatment with Forxiga for at least 3 months, Including: * HbA1c * Weight * Systolic blood pressure * Diastolic blood pressure * Heart rate * Serum creatinine * Estimated glomerular filtration rate * Liver function tests \[Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), or bilirubin\], Baseline and 3 months|Subgroup analyses may be conducted for selected safety parameters, Subgroups to be evaluated will include gender, age, diabetes duration, concomitant medication, past medical history, and measured laboratory variables (if available), Upto 6 months
|
